Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen.

In conclusion, this 10 y-FU update suggests that TILs markers that CD3, FOXP3 and CD8 IHC counts have predictive value by identifying patients with better sensitivity to R-maintenance. Ten years follow-up of PFS (months) according to CD3 IHC scores in the R-maintenance arm (A) and in the control (R-chemo without maintenance) arm (B) of the PRIMA trial. Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen. [Extracted from the article]